Citations

Clear

66 citation(s) found for "McCarty, T P".

Genotype patterns atPICALM, CR1, BIN1, CLU, andAPOEgenes are associated with episodic memory
Barral, Sandra , Bird, Thomas D., Goate, Alison , Farlow, MR, Diaz‐Arrastia, Ramon , Bennett, David A. , Graff-Radford, N. R., Stern, Yaakov , Ott, Jürg , Mayeux, Richard , Kowall, Neil W. , Williamson, Jennifer, Santana, Vincent, Schmechel, Donald E., Gaskel, Peter, Farlow, Martin R. , Faber, Kelley, Horner, Kelly, Growdon, John H., Blacker, Deborah , Tanzi, Rudolph E. , Kuntz, Karen M. , Norgaard, Lindsay, Larson, Nathan, Kistler, Dana, Parfitt, Francine, Haddow, Jenny, Silverman, Jeremy M. , Beeri, Michal Schnaider , Sano, Mary , Wang, Joy , Lally, Rachel, Johnson, Nancy, Mesulam, Marcel, Weıntraub, Sandra , Bigio, Eileen H. , Kaye, Jeffery, Kramer, Patricia, Payne-Murphy, Jessica, Jacobs, Holli, Chang, Joon, Arends, Danielle, Harrell, Lindy, Bartzokis, George, Cummings, Jeffery L., Lu, Po H. , Toland, Usha, Smith, Charles , Brickhouse, Alise, Trojanowski, John Q. , DeKosky, Steven T. , Weamer, Elise A., Chui, Helena C., Varpetian, Arousiak, Rosenberg, Roger N., Schellenberg, Gerard D. , Raskind, Murray A. , Rumbaugh, Malia, Nickel, Kate, Norton, Joanne, Levitch, Denise, Grant, B., Coats, Mary A., Levey, Allen, Rosen, Ami, Anosike, Ezinna, Bennett, David A. , Wilson, Robert S. , Boeve, Bradley F. , Sweet, Robert A. , Wilson, R. J. , Foroud, Tatiana , Green, Robert C. , Farrer, Lindsay A. , Ghetti, Bernardino , Prentice, Heather A. , Hyman, Bradley T. , Larson, Nathan, Kaye, Jeffery, Deerlin, Vivianna M. Van , Wood, Elisabeth McCarty , Davis, Barbara Allen , Morris, John A. , Stern, Yaakov , Goate, Alison M , Diaz-Arrastia, Ramon

Mayo Clinic

Neurology | April 27, 2012 | Volume: 78 | Issue: 19 | Pages: 1464-1471

10.1212/wnl.0b013e3182553c48 | PMID 22539578 Get It

Sexually Abused Girls and Their Rorschach Responses
Friedrich, William N., Einbender, Alison J., McCarty, Peggy

Mayo Clinic

Psychological Reports | August 31, 2011 | Volume: 85 | Issue: 2 | Pages: 355-362

10.2466/pr0.1999.85.2.355 | PMID 10611764 Get It

Exner's scoring (1990) was used on the responses by 46 sexually abused girls (6 to 14 years old) and 46 nonsexually abused girls (6 to 14 years old). Subjects were matched for age, race, family income, and family constellation. Sexually abused children exhibited significantly more unusual content, e.g., sex and blood, in their protocols as well as more frequent coping deficits.
O1‐01‐08: Development of a genetic education and genetic risk disclosure protocol for individuals with mild cognitive impairment
Lautenbach, Denise, Karlawish, Jason , Roberts, J. Scott , Bradbury, Margaret, Uhlmann, Wendy R. , Petersen, Ronald C. , Fafowora, Tolulope, Harkins, Kristin , Zausmer, Lindsay, Green, Robert C. , Obisesan, Thomas O. , Cupples, L. Adrienne , Wood, Elisabeth McCarty

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2011.05.230 Get It

Quality Control Procedures for Genome‐Wide Association Studies
Turner, Stephen , Armstrong, Loren L., Bradford, Yuki, Carlson, Christopher S. , Crawford, Dana C. , Crenshaw, Andrew, Doheny, Kimberly F. , Haines, Jonathan L. , Hayes, Geoffrey, Jarvik, Gail P. , Jiang, Lan , Li, Rongling, Manolio, Teri A. , Matsumoto, Martha, McCarty, Catherine A. , McDavid, Andrew , Mirel, Daniel B., Paschall, Justin, Pugh, Elizabeth, Rasmussen, Luke V. , Wilke, Russell A. , Zuvich, Rebecca L., Ritchie, Marylyn D. , Andrade, Mariza de , Kullo, Iftikhar J. , Ling, Hua , Jarvik, Gail P , Rasmussen, Luke V

Mayo Clinic

Current Protocols in Human Genetics | January 13, 2011 | Volume: 68 | Issue: 1 | Pages: No page available

10.1002/0471142905.hg0119s68 | PMID 21234875 Get It

AbstractGenome‐wide association studies (GWAS) are being conducted at an unprecedented rate in population‐based cohorts and have increased our understanding of the pathophysiology of complex disease. Regardless of context, the practical utility of this information will ultimately depend upon the quality of the original data. Quality control (QC) procedures for GWAS are computationally intensive, operationally challenging, and constantly evolving. Here we enumerate some of the challenges in QC of GWAS data and describe the approaches that the electronic MEdical Records and Genomics (eMERGE) network is using for quality assurance in GWAS data, thereby minimizing potential bias and error in GWAS results. We discuss common issues associated with QC of GWAS data, including data file formats, software packages for data manipulation and analysis, sex chromosome anomalies, sample identity, sample relatedness, population substructure, batch effects, and marker quality. We propose best practices and discuss areas of ongoing and future research. Curr. Protoc. Hum. Genet. 68:1.19.1‐1.19.18 © 2011 by John Wiley & Sons, Inc.
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for P
Micallef, Ivana N. , Stiff, Patrick J. , Bolwell, Brian J., Jacobsen, Eric D. , Nademanee, Auayporn, McCarty, John M. , Bridger, Gary, Calandra, Gary, DiPersio, John F. , Maziarz, Richard Thomas

Mayo Clinic

Journal of Clinical Oncology | August 31, 2009 | Volume: 27 | Issue: 28 | Pages: 4767-4773

10.1200/jco.2008.20.7209 | PMID 19720922 Get It

Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients. Patients and Methods This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible. Patients received granulocyte colony-stimulating factor (G-CSF; 10 μg/kg) subcutaneously daily for up to 8 days. Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until ≥ 5 × 10 6 CD34+ cells/kg were collected. The primary end point was the percentage of patients who collected ≥ 5 × 10 6 CD34+ cells/kg in 4 or fewer apheresis days. Results This report presents all data for all patients (n = 298) through 12 months follow-up. Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001). One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization. Median time to engraftment was similar in both groups. The most common plerixafor-associated adverse events were GI disorders and injection site reactions. Conclusion Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.